



## **Nanomaterials in industrial and international context**

Mark Bünger, Research Director  
Lux Research, Inc.

# Lux Research profile

- Primary research methodology: Focus on proprietary interviews and site visits
  - > 1,400 interviews last year
  - Site visits in 18 countries, China to Dubai
- Clients on five continents
- Delivers value via analyst inquiry, weekly intelligence reports, and semi-annual State of the Market reports
- Retainer-based services in solar, energy storage, nanomaterials, water and life sciences
- Source proprietary ideas from Lux Research Network of execs + scientists
- Diverse, 40-person team; Ph.D scientists to market researchers



Josh Wolfe,  
Director, Lux Research

21<sup>st</sup> Century R&D Act signing in Oval Office



LR Chairman  
Peter Hebert  
on CNBC



LR President Matthew Nordan testifying  
before U.S. Congress

# Our journals and reports provide information and insight for corporations, governments, and universities

**Halozyme Therapeutics** NASDAQ: HALO  
Engineered enzymes for delivery of drugs through the extracellular matrix

**What you need to know**

- Uniquely enabling technology for delivery of injectable drugs
- Strong partnerships with Roche and Baxter, including more than \$60 million in up-front and equity payments and more than \$600 million in potential milestones
- Proving efficacy in clinical trials including delivery of fluids, biologics, and small molecules; proprietary formulations with insulin, chemotherapeutics, and bisphosphonates
- Broad applicability in cancer, diabetes, osteoporosis, and cosmetic/aesthetic medicine

**Scorecard**

**luxtake: Strong positive**

Compare Halozyme Therapeutics to competitors

Metric	Score	Notes
Technology/innovation value	5	Drugmakers lower active cost and extend patents on coformulated drugs; cuts need for IV specialist, saves cost for patient and payor, which will drive adoption
Addressable market size	5	Four of marks therapies
Competitive landscape	4	No dr advan
Barriers to growth	3	Clear
IP position	4	Has a know
Regulatory factors	3	Subje they 4
Management team	3	Seas and m
Partnerships	5	High-
Momentum	4	Main millio
Other	3	Adde early-comp

**Key metrics**

Metric	Category	Value	Date	Comments
Bioavailability	drug delivery systems	90-95% (n/w)	November 18, 2008	Halozyme notes that a typical mAb has ~60% bioavailability in a subcutaneous (SC) injection, and at most about 1 mc

**Key Issue:** Benefits to patients, payors, and physicians.

**What they said:**  
In our discussions, Halozyme emphasized the benefits to all three key stakeholders: patients, payors, and physicians. Patients get a more convenient, less painful way to receive drugs. The payor -- be that insurance company, government, or the patient himself -- gets a lower cost of treatment, because a referral to an IV specialist takes more time and money; additionally, drug costs are lower because the formulation with hyalenas increases bioavailability, reducing the need for the active. Physicians get an additional course of treatment they can offer in their offices, with subcutaneous injections of a new set of drugs.

**What we think:**  
Many treatments benefit one stakeholder at the expense of others, but Halozyme's technology does address key needs at each point in the chain. We believe that most patients will be willing to accept the small reported side effects of redness and swelling at the injection site in order to save a trip to a specialist. The benefit of lower drug cost can't be realized unless the drugmaker passes along lower costs, but we do believe it likely that physicians will opt to offer the subcutaneous injection. With all three stakeholders on board, the technology and related products will fare well in the market.

**History**

Halozyme's current Vice President, Chief Scientific Officer, joined the company in 1998 to develop therapeutic products based on enzymes. In 2004, the company received funding of 1 reverse merger. In late 2004 and 2005, it received 4 in the European Union and in the United States. Also application and received U.S. Food and Drug Administration approval into the clinic. Since then, the company programs, begun direct product sales of Cumulase at Roche and Baxter.

**Technology**

Halozyme focuses on drug delivery and other therapies (EDM). The core technology is a series of engineered in the ECM. The primary technology is HmuH20, a tru that breaks down hyaluronan, a carbohydrate polymer. By locally depolymerizing hyaluronan, HmuH20 opens the order of 200 nm free passage to the circulatory a large-molecule drugs can be injected subcutaneously HmuH20 recombinant version of natural hyaluronidase neutral pH. Since HmuH20 is recombinant version of 1 allergenicity or immunogenicity that plagues bovine an (on the order of micrograms per dose) are required, goods of coformulated biologics. Administering HmuH20 doses of drug to be administered subcutaneously, are which is more time-consuming and expensive, and re

**Financial statistics**

Metric	Value	Date	Comment
Employees	125	Nov 2008	
Revenue	\$3 million	2007	Revenues for the first half of 2008 alone were \$3.2 million
Cash	\$82 million	Jun 2008	
Profitable	No	Nov 2008	Net loss 2007 was \$23.9 million, compared with a net loss of \$14.8 million in 2006.

**Milestones**

Milestone	Impact	Date	Met?
Third major partnership	Would bring additional up-front and milestone payments, plus royalties longer-term	2009	\$60 in the future
Phase III trials for own cancer treatment	Would provide new revenue and validate Halozyme's broad in-house oncology program	2009	\$60 in the future
Phase II trials for own insulin program	Would open up large new markets for diabetes treatment	2009	\$60 in the future
Second enzyme HT501 (collagenase)	Would enable new products, although still in development	2010	Still in development

**Analyst inquiry**  
Questions about Halozyme Therapeutics?  
Email: [h.inquiry@luxresearch.com](mailto:h.inquiry@luxresearch.com)  
or call +1 644 421 6900

**Download PDF**

**Last updated:** November 18, 2008  
**Aliases:** None  
**Parent company:** None  
**Stage of development:** Introduction  
**Interviewed:**  
• Zachary Horvitz (Associate Director, Business Development)  
• Bob Little (Chief Commercial Officer)  
**Business models:**  
• License technology  
• Sell product  
**Process:**  
• Biochemical process

**Alliances Director:** Acquisitions, funding history, key investors, phase in development

**Business Development Manager:** Potential and current partnerships, new opportunities, competitors' interests and deals, licensing data, adjacent technologies, upfront and milestone payments

**Legal/in-house counsel:** IP position, past or current litigation

**Research and Development:** scientific references, new instruments and approaches

...plus market sizes, competitor comparisons, historical data, and more

# Outline


- Nanotechnology in industry and commerce
- Nanotechnology investment and revenue internationally
- Nano EHS trends in science, perception, and regulation
- Recommendations for a way forward

*"California can become 'the place to do nanotech' if we regulate it well. In China everything is nano, for better and for worse. We don't want nano to become the next "GMO" -- nano should keep its head held high."*

# Outline

- **Nanotechnology in industry and commerce**
- Nanotechnology investment and revenue internationally
- Nano EHS trends in science, perception, and regulation
- Recommendations for a way forward

# How most people see nanotech products today



Visionary but Scary  
Imaginary



Mundane and Scary  
Not nano



Visionary and Useful  
Real



Mundane but Useful  
Real

# Nanotech energy creation will emerge in niches

- Today: Flexible, inexpensive, powerful solar cells could make rooftops into generators -- and better align supply and demand
  - Konarka, Nanosys, Nanosolar
- Tomorrow: Nanoporous filters could reform natural gas onboard vehicles for fuel cell applications
- In years: White/industrial nanobiotech might create organisms or organic materials that produce H<sub>2</sub> or EtOH in commercially meaningful quantities
  - Synthetic Genomics, Hydrogen Solar



# Nanotech provides unparalleled improvement to energy distribution

- Today: Aerogel insulators reduce oil pipeline energy costs and logistics/installation costs
  - Aspen Aerogels
- Tomorrow: Batteries with nanostructured electrodes extend hybrid vehicle range 5x, achieving 180MPG and plugin recharging practical
  - Altair, A123
- In years: Carbon nanotube power cables would transmit energy hyperefficiently (10x Cu at 15% of weight)

 ASPEN



 A123  
SYSTEMS

 Altairnano



# State of the art and key developers in electronics nanotechnology



Application	Description	Readiness	Key companies
Transparent conductors	CNTs and metal NPs in a polymer matrix can replace costly indium tin oxide (ITO) in displays and solar PV panels	Development	Eikos, Unidym, Cambrios, Cima Nanotech, Nanofilm, Canatu,
Thermal management	Nanostructured devices can provide active cooling, while highly conductive features can provide thermal contact	Introduction	Nextreme, Applied Sciences, Nanolab, NovaCentrix, IMEC, NanoComp
Displays	CNTs, quantum dots, and nanoscale layers of polymers can improve the properties of displays, including flexibility	Development	Motorola, Samsung, Cambridge Display, QD Vision, Evident, Ntera
Memory technologies	As optical lithography hits its limits of resolution, emerging technologies offer the promise of extending Moore's law	Development	Nantero, EverSpin, NVE Corp., Samsung, Molecular Imprints, IMEC, HP
Printed electronics	RFID and flexible displays will drive the growth in electronics made by printing processes rather than lithography	Development	Kovio, NanoMas, Nano-C, Polyera, Nanoident, Five Star, Bayer, Cima
LEDs and optical components	Nanoscale engineering and NPs like QDs and dendrimers boost LED output and enable precision optical elements	Introduction	API Nanotronics, Nanocs, NanoGram, PPG, Lightwave Logic, NeoPhotonics
Energy storage	Nanostructured electrodes and NP electrode coatings can greatly improve performance for consumer devices	Introduction	Enable IPC, Cap-XX, Primet, Ionova, APowerCap Technologies, ZPower
Barrier coatings	Several efforts use NPs in attempts to create gas barrier coatings impermeable enough for OLED applications	Development	Nova-Plasma, Hybrid Plastics, IMRE (Singapore)
Packaging	Soldering and bonding at lower temperatures protects nearby components, plus other packaging improvements	Introduction	NovaCentrix, Ormecon, Nanodynamics, Reactive Nanotechnologies, Mayaterials
Lithography and process tools	Fullerenes target improved resists, anti-static packaging for semiconductor wafers, and nanoimprint lithography	Scale	Hybrid Plastics, Frontier Carbon, IMEC, Hyperion Catalysis, Nanocyl, Obducat

# Nanotech in Electronics: Key companies


Name	Type	Country	Comments
Reactive Nanotechnologies	Private start-up	U.S.	Its NanoFoil technology is a thin film made of alternating nanoscale layers of aluminum and nickel for bonding various materials together in electronics <b>packaging</b>
Cambrios	Private start-up	U.S.	Silver nanowire dispersions provide a less costly <b>transparent conductor</b> alternative to the indium tin oxide (ITO) currently used in displays
Cambridge Display Technology (CDT)	Public (NASDAQ:OLED)	U.K.	Makes <b>displays</b> from thin films of engineered polymers, such as polyphenylene vinylene (PPV), between electrodes to emit visible light
Nantero	Private start-up	U.S.	Develops CMOS-compatible methods for producing carbon nanotube (CNT)-based semiconductor <b>memory</b> and logic devices
Lightwave Logic	Public (OTC:LWLG)	U.S.	<b>Optical components</b> based on the chromophore perkinamine which is embedded in a polymer, then aligned and spaced out using dendrimers
NanoMas Technologies	Private start-up	U.S.	Conductive metal nanoparticle inks that sinter into solid traces quickly at lower temperatures for <b>printed electronics</b>
Nextreme Thermal Solutions	Private start-up	U.S.	Thermoelectric cooling structures for <b>thermal management</b> made by stacking thousands of interleaved nanoscale layers within a thin-film single crystal
Ionova Technologies	Private start-up	U.S.	Cathode system for supercapacitors and lithium ion (Li-ion) <b>batteries</b> made of a nanostructured conductive material coated with a cobalt-free metal oxide layer
Nova-Plasma	Private start-up	Canada	Developing a flexible and transparent <b>high-barrier coating</b> with glass-like levels of gas permeation
Obducat	Public (Frankfurt:OBD)	Sweden	Nanoimprint lithography <b>processing tool</b> for manufacturing double-sided hard disk drive (HDD) patterned media and high-brightness LEDs

# Nanowire Device Fabrication (with Kayte Fischer, Desai Lab, UCSF)




Nanowire Dimensions:  
40-90 nm diameter  
5-40  $\mu\text{m}$  length



Novel 3D nanowire coating technique  
applied to silica beads




# Cell-Nanowire Interface



Nanoscale features allow interdigitation with microvilli, leading to increased van der Waals force

# Adhesion Under Shear Flow



Nanowires continue to adhere under high shear flow

# Biomimetic Nanowire Coatings for Next Generation Adhesive Drug Delivery Systems

Kathleen E. Fischer,<sup>†,‡,§,+</sup> Benjamin J. Alemán,<sup>||,‡,+</sup> Sarah L. Tao,<sup>∇,+</sup>  
R. Hugh Daniels,<sup>¶,+</sup> Esther M. Li,<sup>||,+</sup> Mark D. Büngrer,<sup>†,‡,+</sup> Ganesh Nagaraj,<sup>†,‡,+</sup>  
Parminder Singh,<sup>†,‡,+</sup> Alex Zettl,<sup>||,‡,+</sup> and Tejal A. Desai<sup>\*,†,‡,§</sup>

*Department of Bioengineering and Therapeutic Sciences, Department of Physiology, University of California, San Francisco, San Francisco, California 94158, UCSF/UCB Joint Graduate Group in Bioengineering, San Francisco, California 94158, Material Science Division of LBNL, Berkeley, California 94720, Center of Integrated Nanomechanical Systems (COINS), Berkeley, California 94720, Department of Physics, University of California, Berkeley, Berkeley, California 94720, The Charles Stark Draper Laboratory, Cambridge, Massachusetts 02139, and Nanosys, Inc., Palo Alto, California 94304*

*Received October 23, 2008; Revised Manuscript Received December 16, 2008*



## ABSTRACT

Without bioadhesive delivery devices, complex compounds are typically degraded or cleared from mucosal tissues by the mucous layer.<sup>1–3</sup> While some chemically modified, microstructured surfaces have been studied in aqueous environments,<sup>4,5</sup> adhesion due to geometry alone has not been investigated. Silicon nanowire-coated beads show significantly better adhesion than those with targeting agents under shear, and can increase the lift-off force 100-fold. We have shown that nanowire coatings, paired with epithelial physiology, significantly increase adhesion in mucosal conditions.

Because of their easy accessibility, large surface area, and rich blood supply, mucous membranes (mucosae), such as intestinal, nasal, ocular, vaginal, and buccal tissues, are frequently targeted for therapeutic drug delivery.<sup>1,6</sup> However, the mucosae present significant barriers to permeation, including a 1–450  $\mu\text{m}$  motile mucous gel layer, tight


transit time in conjunction with chemical degradation produce a relatively low concentration gradient at the cellular surface and thus reduced compound absorption. Specific epithelial targeting agents, such as lectins, adhere to glycosaminoglycans on the cell surface; because these sugars are found in the mucous layer as well, competition between the mucous

# Nanoparticulate reformulations are battling cancer




- **What it does:** Formulates drugs into nanoparticles with improved solubility and bioavailability
- **How it works:** Mechanical milling or chemical processes yield nanoparticles; polymers/stabilizers/surfactants keep them dispersed
- **Stage of development:** Four drugs on market now; many more in pipeline
- **Who's developing it:** APP, Baxter (U.S.), Elan (Ireland), Solubest (Israel), Eurand (Italy)


# Polymeric nanoparticles are targeting genetic disease




Micelle



Liposome





Nanoemulsion (Kereos example)



- **What it does:** Protects active from being attacked by immune system and/or enables triggered release by embedding drug in void or surface of nanosphere
- **How it works:** Phospholipid or polymer monolayer surrounds spherical core; active may be enclosed within core or “dissolved” into GRAS/DMF monolayer
- **Stage of development:** \$100m+ drugs on market (J&J Doxil liposomes)
- **Who’s developing it:** Wide variety; key ones include J&J, Gilead (liposomes); Nanocarrier, Nutralease, Samyang (micelles); Kereos (nanomeulsions)

# Nanotextured materials offer chemical-free control of stem cells


- Preferential differentiation
  - Stem cells adopt bone, muscle or cartilage based on substrate pattern alone -- no biological or chemical signaling (Dalby, Univ Glasgow)
- Maintenance in pre-differentiated state
  - Difficult to proliferate stem cells without inducing differentiation
    - Mouse feeder cells contaminate hESCs with mouse proteins -- all existing Federally-acceptable stem cell lines are contaminated
  - Nanotextured surfaces can facilitate proliferation without differentiation (see F Besenbacher, Univ Aarhus (DK), others)




SEM image of human fibroblast producing large processes in response to polymer islands 95 nm high (Source: Dalby)

# Noninvasive cancer therapy: Magforce


- 15nm dia FeO nanoparticles injected directly into tumor site. Alternating magnetic field (similar to MRI) heats up nanoparticles, destroying tumor from inside with minimal damage to surrounding tissue
- Therapy system and nanoparticles are classified as medical devices, not pharmaceuticals
- Currently in Phase I-III trials versus several types of solid tumors:
  - Glioblastoma multiforme successfully completed with 14 patients (March 2003 - June 2004)
  - Glioblastoma and Astrocytoma, Grade III brain tumor recurrence: 65 patients
  - Prostate carcinoma recurrence after therapy
  - Esophagus carcinoma




# More examples, more conditions



Company: StarPharma  
Condition: HIV  
Particle: Dendrimer  
Mechanism: Receptor blocking  
Stage: Clinical Phase II



Company: Nanospectra  
Condition: Cancer  
Particle: Gold nanoshell  
Mechanism: EPR, IR heating  
Stage: entering Phase I




Company: 3DM Puramatrix  
Condition: Nerve damage (tissue scaffold)  
Particle: synthetic peptide  
Mechanism: in-vivo self-assembling hydrogel  
Stage: small mammal studies


# Outline

- Nanotechnology in industry and commerce
- **Nanotechnology investment and revenue internationally**
- Nano EHS trends in science, perception, and regulation
- Recommendations for a way forward


# The nanotechnology value chain



# Electronics- and healthcare-based nanointermediates do especially well




# Benchmarking 2004 forecast against current estimates



Compared to projection, nanointermediates are much smaller percentage of nano-enabled products

- > More incremental innovations and fewer (high-value) disruptive ones
- > Incremental improvements to more different product categories

# A full force of funding



# U.S. , Japan, and Russia account for 52% of \$8.4 billion government spending




Russia bumps Germany for 3<sup>rd</sup> place

# U.S., Japan, and Germany account for 74% of \$8.6 billion corporate spending



Japan jumps over U.S. for top spot

# Nanotechnology is not limited to large or advanced economies



IRAN: Agriculture-Jihad ministry announces launch of a nanotech research website.

CHINA: Government nanotech initiatives going back to 1987 provide for expansive nanotech research, and nanomaterials suppliers like Sokang Nano proliferate.

TAIWAN: The Industrial Technology Research Institute (ITRI) back a network of nanotech centers to support industry.

BRAZIL: Launches an initiative to spend \$30 million on nanotech research in 2005 and 2006.

INDIA: President Abdul Kalam calls for India to become a leader in nanotechnology.


AUSTRALIA: Nano-biotech start-ups like pSivida and Starpharma develop innovative treatments.

SINGAPORE: State-led initiatives focus on nanoelectronics applications.


THAILAND: Ministry of Science and Technology drafts a ten-year plan to become an Asian nanotech leader.

Source: Lux Research

# VCs splurge as investments jump 60% in 2008



# VC investments aren't informed by exits




# Lux Research evaluated countries on two axes: nanotech activity and development strength


Criterion	Description
Nanotech initiatives	Qualitative assessment of the operational status, effectiveness, and coordination of nanotechnology initiatives at the national, regional, and local levels
Nanotech centers	Number of dedicated government and university nanotech facilities in country with a focus on either R&D or commercialization
Government spending	Amount of funding at regional and national levels specifically allocated to nanotechnology in 2008
Risk capital	Qualitative assessment of availability of risk capital to fund new ventures, taking into account institutional venture capital, government grants, and subsidized loans
Corporate nanotech funding	Estimated spending by established corporations on nanotechnology R&D in 2008, at purchasing power parity
Nanotech publications	Number of articles in scientific journals on nanoscale science and engineering topics from 1995 through 2008
Issued international patents	Number of international patents on nanotech-enabled inventions issued from 1995 to 2008 to entities based in country
Active companies	Qualitative score; considering both number and quality of companies active in nanotech, including large corporations, small and midsize companies, and start-ups

Criterion	Description
High-tech manufacturing as percent of GDP	Value of domestic output for high-tech chemicals, information technology products, pharmaceuticals, and life sciences products for most recent year available divided by GDP in that year
R&D spending as percent of GDP	Gross domestic R&D spending from both government and private-sector sources divided by GDP, for most recent year available
Technology and science workforce	Number of R&D personnel per \$1,000 of GDP at purchasing power parity, for most recent year available
Science and engineering Ph.D.'s	Number of science and engineering Ph.D. graduates as a percent of total population, most recent year available
Expatriation of highly educated	Percent of highly educated leaving country in 2008
Infrastructure	Composite metric composed of electricity availability (2%), mobile phones per capita (2%), Internet hosts per capita (2%), Internet users per capita (2%), and abundance of roads (2%), for 2008


# Evaluated countries on activity and development strength




# U.S. still leads the pack




# Taiwan fails to break through



# China increases development strength



# Italy gains momentum



# Outline

---


- Nanotechnology in industry and commerce
- Nanotechnology investment and revenue internationally
- **Nano EHS trends in science, perception, and regulation**
- Recommendations for a way forward

# All technologies carry risks; we must (and usually do) learn to manage them

The Technology	Internet and cell phones	Genetically-modified organisms	Stem cells
<b>The Bad</b>	<ul style="list-style-type: none"><li>• Viruses</li><li>• Privacy</li><li>• Piracy</li><li>• Porn</li><li>• ADD</li><li>• Brain cancer</li></ul>	<ul style="list-style-type: none"><li>• Frankenfoods</li><li>• Jumping genes</li><li>• Economic displacement</li></ul>	<ul style="list-style-type: none"><li>• Religious issues</li></ul>
<b>The Good</b>	<ul style="list-style-type: none"><li>• Google</li><li>• iPhone</li><li>• YouTube</li></ul>	<ul style="list-style-type: none"><li>• Insulin</li><li>• Less pesticide</li><li>• Drought tolerance</li></ul>	<ul style="list-style-type: none"><li>• Nerve repair</li><li>• Cancer treatment</li><li>• More to come</li></ul>

# Corporate nanotech leaders cite growing cynicism

“What are the challenges facing nanotech development and commercialization today?”



# Three aspects of nanomaterial safety

## Real Risks

Nanomaterials might have negative effects on people or the environment



*Rat exposed to cobalt nanoparticles on the left side, bulk cobalt on the right side*

Best case: Nanomaterials prove to be more dangerous than ordinary substances in only a handful of cases

Worst case: Studies show that many nanomaterials have elevated hazard and are more difficult to control

## Perceived Risks

Nanotechnology might come to be seen as unsafe – irrespective of actual harm




*Protest of the use of Nano-Tex fabric treatment outside an Eddie Bauer store*

Best case: Consumers appreciate the benefits nanomaterials can offer and embrace the technology

Worst case: Nanotech comes to be seen as synonymous with danger and consumers are reluctant to accept it

## Regulations

Regulations might – rightly or wrongly – slow or block commercialization




*Text of the Environmental Protection Agency's Toxic Substances Control Act*

Best case: Existing regulatory frameworks can be painlessly adapted to manage nanomaterials

Worst case: Risks drive regulators to impose stringent testing requirements on all nanomaterials

# Real risks




- Published research into nanotech EHS has increased dramatically since 2004 – 64% of all papers since 1980

## Consumers know little about nano but are optimistic

Researcher(s)	Year	Description	People	Region	Awareness	Attitude	Key finding
BMRB Social Research	2004	Face-to-face survey	1,005	U.K.	Low		Of those who could define it, 68% thought it would improve life
Cobb & Macoubrie	2004	Telephone survey	1,536	U.S.	Low		78% thought benefits would outweigh or be equal to risks
Currall, et al.	2004	Web-based survey	4,543	U.S.	n/a		Average respondent was “quite positive” on a scale of 1 (extremely negative) to 6 (extremely positive)
Scheufele and Lewenstein	2004	Telephone survey	706	U.S.	Low		52% supportive of nanotech, with more-aware respondents more supportive
Lee, Scheufele, and Lewenstein	2004	Telephone survey	706	U.S.	Low		Benefits outweigh risks; both knowledge of and emotion about nanotech affect by how much
Gaskell, et al. (Eurobarometer)	2005	Face-to-face survey	25,000	Europe	Low		40% optimistic about nanotech, 5% pessimistic, 42% don't know the effect
Macoubrie	2005	Face-to-face focus groups	177	U.S.	Low		After discussions completed, 50% of participants were mostly or quite positive

# SUPPORT: NOT MUCH HAS CHANGED

Percentage of people who “overall support (or oppose) the use of nanotechnology”



Note: DK/NA responses varied between 4 and 19 respondents and are not plotted here.




CNS-ASU research, education and outreach activities are supported by the National Science Foundation under cooperative agreement #0531134.

Elizabeth A. Corley & Dietram A. Scheufele

**All Hands Meeting**  
April 19-21, 2007 / Tempe, Arizona

# PERCEIVED BENEFITS: 2004 and 2007




CNS-ASU research, education and outreach activities are supported by the National Science Foundation under cooperative agreement #0531194.

Elizabeth A. Corley & Dietram A. Scheufele

**All Hands Meeting**  
April 19-21, 2007 / Tempe, Arizona

# PERCEIVED RISKS: 2004 and 2007




# Regulation




- Regulatory agencies are looking for data before making any nano-specific regulations
  - Data has been sloooooow in coming
- Lawyers are ramping up nanomaterials practices because of murkiness in existing regulations
- Local governments eye regulations (Berkeley, Cambridge, Wisconsin, Canada)


# Manufacturing




# Use




# End of life



# Lux Research estimates hazard and exposure by life cycle, material, and application



Hazard/risk level:





Exposure:



	Nanoporous silicon	Dendrimers	Single-wall carbon nanotubes
Structural composite for auto body			
Drug			
Memory chip			

# ...for dozens of applications



	Single-walled carbon nanotubes	Multi-walled carbon nanotubes	Nanoclay particles	Cadmium-selenide quantum dots	Zinc oxide nanoparticles	Titanium dioxide nanoparticles	Dendrimers	Fullerenes	Nanocrystalline drug formulations	Silicon nanowires
In vivo imaging	High hazard, High exposure			High hazard, High exposure			Medium hazard, High exposure	High hazard, High exposure		
Structural composite for automotive body	High hazard, High exposure	Medium hazard, High exposure	Low hazard, High exposure					High hazard, High exposure		
Sunscreen additive					Medium hazard, High exposure	Low hazard, High exposure	Medium hazard, High exposure	High hazard, High exposure		
Food additive					Medium hazard, High exposure	Low hazard, High exposure	Medium hazard, High exposure	High hazard, High exposure		
Display backplane	High hazard, High exposure									Low hazard, High exposure
Polishing agent					Medium hazard, High exposure	Low hazard, High exposure				
Memory chip	High hazard, High exposure			High hazard, High exposure				High hazard, High exposure		Low hazard, High exposure
Printer toner							Medium hazard, High exposure			
Drug							Medium hazard, High exposure	High hazard, High exposure	Low hazard, High exposure	
Flexible solar cell				High hazard, High exposure		Low hazard, High exposure		High hazard, High exposure		Low hazard, High exposure

# Other nano-EHS observations

- The number companies producing or directly handling nanoparticles will continue to grow.
  - A “do not touch” policy would risk losing increasing amounts of business
- Nanoparticles should not be treated as a class of materials by regulators or insurers.
  - Make a value vs risk assessment and update as EHS knowledge grows.
- Larger companies know what they’re doing; small(er) companies....not so sure.
  - Approach coverage of small companies carefully for nanoparticles with significant risk, or significant uncertainty. Learn from large companies.
- End of Life issues are lagging in terms of data development and understanding.
  - The biggest risk for insurers at the nanoenabled product part of the value chain. Need to build internal policies while this knowledge gap is addressed
- **The landscape will be a lot clearer in 3-5 years; stay engaged now**

# Outline

- Nanotechnology in industry and commerce
- Nanotechnology investment and revenue internationally
- Nano EHS trends in science, perception, and regulation
- **Recommendations for a way forward**

# Nanotech EHS: Recommendations


- Nanotech companies should volunteer information about their nanomaterials to agencies and publics when and before they request it
- Regulators should tighten the feedback cycle for information gathering to less than 1 year
- Investors must scrutinize the EHS policies of nanomaterials companies (and ANY companies) they fund




# What's the outlook over the next five years?

- Global economics force nanotech developers to aim at near-term applications to generate cash
- Electronic materials become all the rage
- New industry clusters emerge
- 2009 administration changes in U.S. accelerate regulations
- Flood gates open for food and personal care applications
- Nanotech overtakes entire industries, and the term “nano” fades from view

# How did we get here? Where do we go next?



Apple





**Thank you**

**Mark Bünger**

Research Director

mark.bunger@luxresearchinc.com

For more information, please see:

**<http://www.luxresearchinc.com/info/nanomaterials>**